Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on June 30, 2021, a capital increase of 306,800 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, and to other investors through its Open Market Sale AgreementSM with Jefferies LLC. As a result, the Company’s share capital is increased to 53,912,224.33 EUR and is represented by 15,493,956 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 30 June 2021 following the Capital Increase:
| Total amount of share capital (EUR) | 53,912,224.33 |
| Total Number of shares with single voting rights | 13,125,931 |
| Total Number of shares with double voting rights | 2,368,025 |
| Total Number of Shares | 15,493,956 |
| Total of voting rights | 17,861,981 |
| Total number of attributed warrants | 1,922,423 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 1,922,423 |
| Total number of diluted shares (Outstanding shares + Warrants) | 17,416,379 |
| Total number of diluted shares with voting rights | 19,784,404 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
